Lv1
47 积分 2020-10-26 加入
Nahya Salim Masoud: improving newborn health in Tanzania
12小时前
已关闭
No surgical innovation without evaluation: the IDEAL recommendations
2天前
已完结
Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial
21天前
已完结
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
21天前
已完结
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
21天前
已完结
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
21天前
已完结
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
21天前
已完结
Data reproducibility issues and their potential impact on conclusions from evidence syntheses of randomized controlled trials in sleep medicine
1个月前
已完结
Rapid evidence synthesis approach for limits on the search date: How rapid could it be?
1个月前
已完结
Archie Cochrane and his legacy
1个月前
已完结
皖公网安备34019202002308
